Reply: Baricitinib Versus Tocilizumab for the Treatment of Moderate to Severe COVID-19

Reid NK Joyner KR Lewis-Wolfson TD . Baricitinib versus tocilizumab for the treatment of moderate to severe COVID-19 [published online ahead of print October 29, 2022]. Ann Pharmacother. doi:10.1177/10600280221133376

Hill JB Garcia D Crowther M , et al. Frequency of venous thromboembolism in 6513 patients with COVID-19: a retrospective study. Blood Adv. 2020;4:5373-5377. doi:10.1182/bloodadvances.2020003083

COVID-19 Treatment Guidelines Panel. Coronavirus disease 2019 (COVID-19) treatment guidelines. National Institutes of Health. Date unknown. Accessed November 11, 2022. https://www.covid19treatmentguidelines.nih.gov/

REMAP-CAP Investigators Gordon AC Mouncey PR , et al. Interleukin-6 receptor antagonists in critically ill patients with COVID-19. N Engl J Med. 2021;384(16):1491-1502.

RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397(10285):1637-1645.

Horby P Staplin N Haynes R Landray M . Tocilizumab in COVID-19 therapy: who benefits, and how? authors’ reply. Lancet. 2021;398(10297):300.

Gorog DA Storey RF Gurbel PA , et al. Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium. Nat Rev Cardiol. 2022;19:475-495. doi:10.1038/s41569-021-00665-7